ADVERTISEMENT

Conference Report

EAS 2022 — Are incretins the key to CVD prevention in the era of obesity and diabetes?

Pavankumar Kamat   |   26 May 2022

In the opening CME session at EAS 2022 chaired by Lale Tokgözoğlu, Turkey and Kausik K. Ray, United Kingdom, experts discussed the role of incretin therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in atherosclerosis and their potential in preventing adverse cardiovascular outcomes in an era where the prevalence of obesity and...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right